Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice
Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani, Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani
Abstract
Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences. At present, the only recommended treatment of CCM is surgical. Because surgery is often not applicable, pharmacological treatment would be highly desirable. We describe here a murine model of the disease that develops after endothelial-cell-selective ablation of the CCM3 gene. We report an early, cell-autonomous, Wnt-receptor-independent stimulation of β-catenin transcription activity in CCM3-deficient endothelial cells both in vitro and in vivo and a triggering of a β-catenin-driven transcription program that leads to endothelial-to-mesenchymal transition. TGF-β/BMP signaling is then required for the progression of the disease. We also found that the anti-inflammatory drugs sulindac sulfide and sulindac sulfone, which attenuate β-catenin transcription activity, reduce vascular malformations in endothelial CCM3-deficient mice. This study opens previously unidentified perspectives for an effective pharmacological therapy of intracranial vascular cavernomas.
Keywords: cerebral cavernous malformation; endothelial cells; sulindac metabolites; vascular pathology; β-catenin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Source: PubMed
今後の臨床試験
-
Shirley Ryan AbilityLabKiwanis Neurological Research Foundation募集
-
University of ChicagoNational Heart, Lung, and Blood Institute (NHLBI)まだ募集していません
-
Fundacion para la Investigacion Biomedica del Hospital...Hospital Universitario La Fe募集
-
Lumetry Diagnostics GmbHKarl Landsteiner Institute for Lung Research and Pneumological Oncology; Klinik Floridsdorfまだ募集していません
-
Beijing Suncadia Pharmaceuticals Co., Ltd募集
-
Xiangya Hospital of Central South Universityまだ募集していません
-
Halic Universityまだ募集していません睡眠の質 | 食事介入 | 知覚ストレス | 物忘れトルコ(Türkiye)
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universityまだ募集していません転移性乳がん | ホルモン受容体陽性乳がん | HER2-low 乳がん中国
-
The 108 Military Central HospitalVietnam Military Medical University; Thanh Phuong Co., Ltdまだ募集していません
-
University Hospital, Montpellierまだ募集していません
-
Kasr El Aini Hospital募集